JOHN M. EVANS, M.D.; RASHID A. MASSUMI, M.D.
Sodium and water retention continues to be the core problem in the management of congestive heart failure. Current practices of diuretic therapy with mercury compounds have vastly improved the management of this problem. However, the necessity of using mercury by injection imposes the limitations of inconvenience, expense and limited acceptability by the patient. In addition, there is an appreciable incidence of side effects, varying in severity from local irritation to the rare death from hypersensitivity or cardiac arrhythmia.1-8
The continuing search for a satisfactory oral dosage form recently resulted in the development of 3-chloro-mercuri-2-methoxy-propylurea, Neohydrin.(The continuing search for a satisfactory oral dosage form recently resulted in the development of 3-chloro-mercuri-2-methoxy-propylurea, Neohydrin.†9 This is a crystalline non-ionic)9 This is a crystalline non-ionic
JOHN M. EVANS, RASHID A. MASSUMI. THE LONG-TERM USE OF THE ORAL DIURETIC 3-CHLORO-MERCURI-2-METHOXY-PROPYLUREA (NEOHYDRIN) IN AMBULATORY PATIENTS(THE LONG-TERM USE OF THE ORAL DIURETIC 3-CHLORO-MERCURI-2-METHOXY-PROPYLUREA (NEOHYDRIN) IN AMBULATORY PATIENTS*). Ann Intern Med. 1956;44:124–132. doi: 10.7326/0003-4819-44-1-124
Download citation file:
Published: Ann Intern Med. 1956;44(1):124-132.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use